• 생물환경조절학회지
• /
• 제23권1호
• /
• pp.26-30
• /
• 2014

본 연구에서는 과수의 형태, 거리에 따라 약대가 항상 적정 살포 거리를 유지하며 작업을 진행할 수 있도록 초음파 센서의 신호를 실시간으로 받아 약대를 제어하였고, 또한 약대의 보호를 위하여 진행 방향에 장애물이 존재할 경우 회피할 수 있도록 프로그래밍 하였다. 제작된 시스템으로 현장에서 비 자동제어 상태와 자동제어 상태로 실험을 수행하였다. 실험은 과수의 기둥과 잎 부위에 감수지를 일정간격으로 설치하고 시스템을 이용하여 분사한 후 감수지의 영상을 스캔하여 영상처리를 통해 분석하는 방법으로 이루어졌다. 상 방향 분사 실험에서는 시스템과 대상의 거리가 0.9m~1.1m로 설정해둔 적정거리를 벗어나지 않았기 때문에 비 자동제어와 자동제어 상태 모두 양호한 결과를 보였다. 하지만 측 방향 분사 실험에서는 비 자동제어 시 우측 열은 98.09%의 분사율을 보였으나 좌측 열은 69.25%로 낮게 나타났다. 이는 실험이 수행된 배 과원의 경우 과수의 좌측 열이 수평하게 식재되어 있지 않았기 때문으로 비자동제어 상태에서는 좌측열의 과수에 분사되는 양이 줄어들었으나 자동제어 상태에서는 좌, 우측열의 과수에 분사되는 양이 각각 92.66%, 94.64%로 균일하게 나타났다. 시스템의 제어 속도를 측정하기 위하여 방향 별 약대의 속도를 측정하였고 각각의 속도는 수직방향 100mm/s, 수평 방향 100mm/s, 각 변화 3o/s로 측정되었다. 초기 목적했던 바와 같이 과수의 형태, 거리에 따라 약대가 적정 거리를 유지하며 작업을 진행함으로 인해서 균일한 살포량을 유지 할 수 있음을 확인하였다.

• Journal of Pharmaceutical Investigation
• /
• 제41권1호
• /
• pp.31-36
• /
• 2011

$5HT_{2C}$ receptor among fourteen 5-HT subtypes plays important roles in several disorders such as depression, anxiety, epilepsy, schizophrenia and sleep disorders. The purpose of the study is to investigate pharmacokinetic parameters and bioavailability of a newly synthesized selective agonist of $5-HT_{2C}$ receptor, KOPC-20010 (KP10) in rats after intravenous and oral administration for the development of therapeutic anti-obesity agents. KP10 was administered orally (40 mg/kg) or intravenously (20 mg/kg), blood was collected via a catheter, and analyzed by GC/MSD. The calibration curve of KP10 in plasma and urine showed high linearity ($r^2$ >0.999). The retention times of KP10 in plasma and urine were 8.7 and 9.7 min, respectively. After oral administration of 40 mg/kg, pharmacokinetic parameters were calculated as follows; $C_{max}$ value was $1242.9{\pm}1195.5$ ng/mL at $1.1{\pm}0.6$ hr ($T_{max}$). $AUC_{0->24hr}$ and $AUC_{0>{\infty}}$ were $8034.2{\pm}960.7$ and $10464.1{\pm}681.5\;ng{\cdot}hr/mL$, respectively. The terminal half-life was $21.9{\pm}7.6$ hr. $AUC_{0->24hr}$ and $AUC_{0>{\infty}}$ were $4292.4{\pm}523.0$ and $6111.2{\pm}756.2\;ng{\cdot}hr/mL$, respectively, after 20 mg/kg of intravenous administration. The terminal half-life after intravenous administration was $25.1{\pm}9.4$ hr. Bioavailability of KP10 was determined to 86%. The excretion amount into the urine within 48 hr was approximately 4.7 to 6.7% of the dose administered. These data may be beneficial to the anti-obesity drug development of KP10.

• Archives of Pharmacal Research
• /
• 제26권7호
• /
• pp.564-568
• /
• 2003

Pharmacokinetic and pharmacodynamic properties of gliclazide were studied after an oral administration of gliclazide tablets in healthy volunteers. After an overnight fasting, gliclazide tablet was orally administered to 11 volunteers; Additional 10 volunteers were used as a control group (i.e., no gliclazide administration). Blood samples were collected, and the concentration determined for gliclazide and glucose up to 24 after the administration. Standard pharmacokinetic analysis was carried out for gliclazide. Pharmacodynamic activity of the drug was expressed by increase of glucose concentration ($\Delta$PG), by area under the increase of glucose concentration-time curve ($AUC_{$\Delta$PG}$) or by the difference in increase of glucose concentration ($D_{$\Delta$PG}$) at each time between groups with and without gliclazide administration. Pharmacokinetic analysis revealed that $C_{max}, T_{max}$, CL/F (apparent clearance), V/F (apparent volume of distribution) and half-life of gliclazide were $4.69\pm1.38 mg/L, 3.45\pm1.11 h, 1.26\pm0.35 L/h, 17.78\pm5.27 L, and 9.99\pm2.15 h$, respectively. When compared with the no drug administration group, gliclazide decreased significantly the $AUC_{$\Delta$PG}$ s at 1, 1.5, 2, 2.5, 3 and 4 h (p＜0.05). The $\Delta$PGs were positively correlated with $AUC_{gliclazide}$ at 1 and 1.5 h (p＜0.05), and the correlation coefficient was maximum at 1 h (r = 0.642) and gradually decreased at 4 h after the administration. The $AUC_{$\Delta$PG}$s were positively correlated with $AUC_{gliclazide}$ at 1, 2, 3 and 4 h (p＜0.05), and the maximum correlation coefficient was obtained at 2 h (r=0.642) after the administration. The $D_{$\Delta$PG}$ reached the maximum at 1 h, remained constant from 1 h to 3 h, and decreased afterwards. Therefore, these observations indicated that maximum hypoglycemic effect of gliclazide was reached at approximately at 1.5 h after the administration and the effect decreased, probably because of the homeostasis mechanism, in health volunteers.

• 농업과학연구
• /
• 제41권4호
• /
• pp.335-339
• /
• 2014

Cowpea chlorotic mottle virus (CCMV)는 Group IV positive sense single strand RNA virus, Bromoviridae과, Bromovirus속으로 분류하는 식물병원성 바이러스로, 강낭콩(Phaseolus vulgaris), 나비완두(Clitoria ternatea), 담배(Nicotiana tabaccum), 대두(Glycine max), 동부(Vigna unguiculata, Vigna siensis) 및 땅콩(Arachis hypogaea)이 국내로 수입될 경우, 검사를 수행하는 관리급 검역바이러스이다. 본 연구에서는, RT-PCR, nested PCR 및 유전자-삽입 양성대조구를 개발하여, CCMV를 현장에서 신속, 정확하게 진단할 수 있는 정밀검정 시스템을 구현하였다. 본 연구에서 개발한 방법은 지속적으로 현장에서 활용되어 식물검역에 기여할 것이라고 기대된다.

• 한국식품영양학회지
• /
• 제30권4호
• /
• pp.735-741
• /
• 2017

This study was conducted to investigate if the supplement formula may improve alcohol metabolism in healthy adult men. In a double-blinded, randomized, crossover study, subjects were administrated yeast extract mixtures (YEM, n=15), Hovenia dulcis mixtures (HDM, n=15), placebo (PLA, n=15), and control (CON, n=15) in an oral dose followed by one week washout periods. At each visit (0, 1, 2, 3, 4 week), subjects drank 450 mL, 20.1 percent alcohol after administered mixtures. Blood was drawn periodically (0, 0.25, 0.5, 1, 2, 4, 6, 15 hours). Fifteen subjects completed the protocol and were included in the analysis. Plasma ethanol concentration was lower in YEM (10 percent) and the HDM (5 percent) groups. The area under the curves (AUC) and $C_{max}$ for plasma ethanol were significantly decreased only in the YEM group, when compared with the CON group. The AUC and $C_{max}$ for plasma acetaldehyde concentration were significantly decreased in the YEM (45 and 54 percent) and the HDM (35 and 53 percent) groups respectively, when compared with PLA (p<0.01). Together, these findings validate that YEM or HDM improved alcohol metabolism and hangover syndromes, leading to reduce alcohol concentration and acetaldehyde concentration without adverse effects.

• 한국임상수의학회지
• /
• 제36권3호
• /
• pp.159-165
• /
• 2019

Pimobendan is an inodilator used to treat canine heart failure, and pentoxifylline is reported to be beneficial for microcirculation and heart disease. The purpose of this study was to evaluate the pharmacokinetic and pharmacodynamic profiles of a novel pimobendan-pentoxifylline liquid mixture after oral administration to dogs. Eight healthy Beagle dogs were included in the study. The dogs were divided into the control group (orally administered water; n = 4) and experimental group (orally administered pimobendan-pentoxifylline liquid mixture [pimobendan 0.25 mg/kg, pentoxifylline 15 mg/kg]; n = 4). Plasma samples were obtained and echocardiographic indices were measured for 24 hours after administration. The concentrations of pimobendan and pentoxifylline were quantified by using a liquid chromatography-mass spectrometer (LC-MS). The elimination half-life ($T_{1/2}$) was $32.96{\pm}9.80mins$ for pimobendan and $29.49{\pm}6.67mins$ for pentoxifylline. The time to reach maximum concentration ($T_{max}$) were $52.50{\pm}31.22mins$ for pimobendan and $41.25{\pm}18.87mins$ for pentoxifylline. The maximum blood concentration ($C_{max}$) was $96.92{\pm}75.64ng/mL$ for pimobendan and $7074.07{\pm}3261.1ng/mL$ for pentoxifylline. Of the echocardiographic indices, fractional shortening (FS) and left ventricular internal diameter at end systole (LVIDs) were significantly altered at 1-3 hours after the administration of pimobendan-pentoxifylline liquid mixture. The pimobendan-pentoxifylline liquid mixture was well tolerated by the dogs, with no adverse effects observed during the study.

• 한국결정성장학회지
• /
• 제21권6호
• /
• pp.230-234
• /
• 2011

$CF_4$ Ar 및 $SF_6$/Ar 유도결합 플라즈마을 이용하여 ZnO 박막의 고이온밀도 플라즈마 식각을 수행하였다. $10CF_4$/5Ar, $10SF_6$/5Ar 유도결합 플라즈마에서 최고 ~1950 ${\AA}$/min과 ~1400 ${\AA}$/min의 식각 속도를 확보하였다. 대부분의 조건 하에서 식각된 ZnO 표면은 식각 전보다 더 낮은 표면조도 값들을 나타내었다. $10CF_4$/5Ar 유도결합 플라즈마에서 Ni mask는 ZnO에 대해 최고 11의 높은 식각 선택도를 나타낸 반면에 Al은 이보다 낮은 1.6~4.7 범위의 식각선택도를 나타내었다.

• Journal of Pharmaceutical Investigation
• /
• 제22권2호
• /
• pp.125-131
• /
• 1992

The effects of domperidone, scopolamine butylbromide and cimetidine on the absorption and bioavailability of ciprofloxacin were studied in female rats. Ciprofloxacin was given in a single oral dose of 30 mg/kg to control group. Ciprofloxacin was concurrently administered with domperidone $(T_1\;group)$, scopolamine butylbromide $(T_2\;group)$, and cimetidine $(T_3\;group)$ to rats, respectively. Significantly changed pharmacokinetic parameters observed in $T_2$group when compared with control group were first-order absorption rate constant, $Ka(4.43{\pm}0.85$\;versus\;2.86{\pm}0.41\;hr^{-1},\;p<0.05)$, time needed to reach peak concentration, $T_{max}\;(32.27{\pm}2.46\;versus\;51.75{\pm}5.51\;min,\;p<0.05)$, area under the plasma concentration-time curve, AUC $(332{\pm}19\;versus\;477{\pm}27\;{\mu}g{\cdot}min/ml,\;p<0.05)$ and absolute bioavailability, Fabs $(60.6{\pm}3.6\;versus\;87.0{\pm}5.0%,\;p<0.05)$. On the other hand, domperidone and cimetidine did not significantly affect the absorption of ciprofloxacin. It is suggested that when scopolamine butylbromide is selected for clinical use, there is need for awareness of the reduction in absorption rate and the enhancement in absorption extent of ciprofloxacin.

• 전자공학회논문지C
• /
• 제36C권6호
• /
• pp.52-62
• /
• 1999

본 논문에서는 가상 환경에서 움직이는 인체 Avatar의 움직임을 인간의 가장 자연스러운 동작의 하나인 손 제스처를 이용하여 실시간으로 제어하는 인식 시스템의 구현에 관하여 상술한다. 동적 손 제스처는 컴퓨터와 제스처를 사용하는 사람과의 상호 연결 수단이다.가상공간 상에서의 자연스러운 움직임을 표현하기 위해 32개의 자유도(DOF)를 가진 인체 아바타를 구성하였으며, 정지, 전후좌우로 한 걸음 이동, 걷기, 달리기, 좌우로 회전, 뒤로 돌기, 물건 잡기의 동작 모드를 정의하여 가상공간 상의 인체 아바타는 미리 설정된 손 제스처에 따라 실시간에 따라 실시간으로 3차원공간상에서 움직일 수 있다. 실시간의 인체 아바타 이동에는 역 기구학과 기구학을 혼용하여 적용하였으며, 사이버 터치를 착용한 사용자의 손 제스처 인식에는 인공 신경망 이론과 퍼지 이론을 도입하여 실시간 인식이 가능하였다.

• 한국임상수의학회지
• /
• 제36권1호
• /
• pp.46-52
• /
• 2019

Pimobendan has inotropic and vasodilating effects on cardiovascular system, and pentoxifylline is known to decrease blood viscosity and improve blood flow to the heart. This study investigated the pharmacokinetics and pharmacodynamics following oral administration of pimobendan-pentoxifylline powder mixture in dogs. Eight healthy dogs were included and were divided into control (n = 4) and experimental (n = 4) groups. Vehicle powder and pimobendan-pentoxifylline powder mixture (pimobendane 0.25 mg/kg, pentoxifylline 15 mg/kg) were administrated orally to control and experimental groups, respectively. Plasma samples and measurement of echocardiographic indices were obtained for 24 hours following administration. Pimobendan and pentoxifylline concentrations were investigated using liquid chromatography-mass spectrometer (LC-MS) assay. The elimination half-life ($T_{1/2}$) were $2.65{\pm}1.42hours$ for pimobendan and $0.29{\pm}0.23hours$ for pentoxifylline. The time to reach maximum concentration ($T_{max}$) were $1.08{\pm}0.72hours$ for pimobendan and $0.29{\pm}0.14hours$ for pentoxifylline. The maximum blood concentration ($C_{max}$) were $2.83{\pm}1.50ng/mL$ for pimobendan and $1184.33{\pm}932.37ng/mL$ for pentoxifylline. Among echocardiographic indices, fractional shortening (FS), left ventricular internal diameter at end systole (LVIDs), and pre-ejection period (PEP) showed significant changes at 1-4 hours after the administration of pimobendan-pentoxifylline powder mixture. No adverse effects were observed during the investigation. This study demonstrates that pimobendan-pentoxifylline powder mixture can be used to control cardiovascular diseases in dogs.